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RESUME 
Les deux publications de ce travail caractérisent les effets chez l'homme d'un 
inhibiteur de l'en.Zyme de conversion de !'angiotensine et d'un antagoniste de 
l' angiotensine II, ces deux substances permettant de bloquer l'axe rénine-
angiotensine à deux niveaux différents. 
Dans la première publication de ce travail, différentes méthodes de mesure 
du degré d'inhibition de l'axe rénine-angiotensine ont été comparées entre 
elles lors de l'administration du temocapril, un nouvel inhibiteur de l'enzyme 
de conversion testé pour la première fois chez l'homme. Les taux 
plasmatiques du métabolite actif, les taux plasmatiques d'angiotensine I et 
d'angiotensine II, l'activité plasmatique de l'enzyme de conversion de 
!'angiotensine et l'effet presseur d'injections intraveineuses d'angiotensine I 
ont été déterminés de manière répétée avant et après l'administration en 
double aveugle de 4 différentes doses de temocapril ou de placebo. Le 
rapport de la concentration de l' angiotensine II sur celle de l' angiotensine I 
s'est avéré le paramètre le mieux correllé à la fois aux concentrations de 
métabolite actif (r=-0.85, n=148) et à l'élévation de pression systolique et 
diastolique produite par l'injection d'angiotensine I (r=0.76 et r=0.79, 
respectivement, n=148). Le rapport angiotensine II/ angiotensine I est en 
conclusion un paramètre très fiable permettant de déterminer le degré 
d'inhibition de l'enzyme de conversion. 
Le but de la deuxième étude était de caractériser l'effet d'une substance 
bloquant les récepteurs de l' angiotensine II, le TCV-116, chez des volontaires 
normotendus. Quatre différentes doses de TCV-116 (1, 2, 4 et 8 mg) ou un 
placebo ont été administrées en double aveugle pendant 8 jours à 27 
volontaires. Le taux de métabolite actif, les concentrations plasmatiques 
d'angiotensine II, d'aldostérone, de noradrénaline et d'adrénaline, l'activité 
de la rénine plasmatique, de même que la réponse de la pression systolique, 
diastolique et du rythme cardiaque à un bolus intraveineux d'angiotensine II, 
ont été déterminées de façon répétitive (n= 17). Le TCV-116 a diminué de 
façon dose-dépendante la réponse pressive à !'angiotensine IL Six heures 
après une dose de 4 mg de TCV-116, la réponse pressive à !'angiotensine II 
s'est abaissée à 40 ± 4 % de la valeur initiale (moyenne± SEM, n=6) le jour 1 
et à 35 ± 8 % le jour 8 du traitement. Les résultats démontrent que le TCV-116 
bloque de façon prolongée le système rénine-angiotensine à des doses 7 à 9 
fois moins élevées que le losartan, seul antagoniste de l' angiotensine II alors 
étudié chez l'homme. Par ailleurs, le délai entre une concentration 
plasmatique donnée du métabolite actif et son effet clinique (inhibition de 
l'augmentation de pression induite par un bolus intra-veineux d'angiotensine 
II) au site d'action (hystérèse) a été déterminé pour la première fois lors de 
l'administration d'un antagoniste de !'angiotensine IL Enfin, malgré une 
élévation très importante des concentrations plasmatiques d' angiotensine II 
et de l'activité plasmatique de la rénine induite par le bloquage des 
récepteurs à l'angiotensine II dès la première dose, aucune diminution de 
l'effet du TCV-116 n'a été constatée au huitième jour de traitement. 
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Value of Different Clinical and Biochemical Correlates to 
Assess Angiotensin Converting Enzyme Inhibition 
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*Philip R. Robinson, Bernard Waeber, and Hans R. Brunner 
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Summary: In a double-blind study, we compared the 
value of different approaches to assess blockade of an-
giotensin (Ang) II generation in 10 normal volunteers 
treated with the new Ang-converting enzyme (ACE) in-
hibitor temocapril. Plasma concentration of the diacid ac-
tive metabolite oftemocapril, plasma Ang I and II levels, 
plasma ACE activity, and inhibition of the pressor re-
sponse to repeated intravenous (i.v.) doses of Ang I were 
measured before and repeatedly after different doses of 
temocapril or placebo. In vivo ACE activity, estimated 
by the plasma Ang 11/Ang I ratio, correlated well with 
Angiotensin (Ang)-converting enzyme (ACE) in-
hibitors are now widely used in treatment of pa-
tients with hypertensive disorders (1-7) and with 
congestive heart failure (CHF) (8-11). Because of 
their efficacy, interest in these therapeutic agents 
has grown tremendously in recent years; several 
new compounds have been developed, and many 
are being investigated. 
Many years ago, it was demonstrated that the 
magnitude of blockade achieved by ACE inhibition, 
the minimum dose needed for maximal efficacy, 
and onset and duration of action of the agents can 
be determined with great accuracy by challenging 
normotensive volunteers with repeat intravenous 
(i. v.) administrations of Ang I (12). The ability of 
ACE to cleave various natural and synthetic sub-
strates has been used to measure its aètivity in 
vitro. For drug monitoring in patients treated with 
ACE inhibitors, plasma ACE activity measured in 
vitro provides consistently reproducible results al-
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temocapril diacid concentration (r = 0.85, n = 148) and 
with systolic and diastolic blood pressure (SBP, DBP) 
responses to Ang I (r = 0.76 and r = 0.79, n = 148). SBP 
and DBP responses to Ang I were also strongly related to 
temocapril diacid concentration (r = -0.81 and r = 
-0.88, n = 148). ACE activity measured in vivo reliably 
predicts the decrease in Ang-dependent BP to be 
achieved by ACE inhibitors. Key Words: Temocapril-
Angiotensin converting enzyme inhibition-Angiotensin 
11/Angiotensin I ratio-Dose-response relationship-
Blood pressure. 
though absolute ACE activity varies considerably 
depending on substrates and assay conditions used 
(13). Finally, because ACE inhibition causes 
plasma Ang II to decrease and Ang I concentration 
to increase, an alternative approach to estimating 
degree of inhibition of ACE activity in vivo is to 
measure plasma concentrations of Ang I and Ang II 
and to use the ratio Ang II/ Ang I as an estimate of 
in vivo ACE inhibition (14). 
We assessed and compared the accuracy of the 
three different approaches described to estimate the 
degree of inhibition of ACE activity, the degree of 
inhibition of the pressor effect of an i. v. bolus of 
Ang I, ACE activity in vitro measured with two 
different substrates, and the Ang II/Ang I ratio (es-
timating ACE activity in vivo). The new ACE in-
hibitor temocapril is a prodrug that is converted by 
deesterification in blood, li ver, and intestinal wall 
(15) to the pharmacologically active metabolite 
temocapril diacid. After we assessed the pharmaco-
Brunner at Division of Hypertension CHUV, 1011 Lausanne, 
Switzerland. 
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FIG. 2. Maximal systolic blood pressure (SBP) and diastolic 
BP (DBP) increase (mm Hg, mean + SD) after repeated (n = 
30) intravenous bolus of Ang 1 in the 4 volunteers receiving 
placebo on 5 different days (top) and variation coefficients 
(%) of maximal presser effect of Ang 1 (bottom). 
teers who entered the study completed it as 
planned. 
BP response to Ang I 
Values of BP and HR before and after ("peak 
value") Ang I challenge are summarized in Table I. 
The inhibitory effect of temocapril on bath SBP and 
DBP responses to Ang I was dose dependent (Fig. 
1). With all doses, maximum effect was observed 
within the first 2 h. The lowest dose (2.5 mg) pro-
duced an inhibition of the Ang I effect of 47 ± 6% 
(SBP) and 65 ± 8% (DBP), and the highest doses (20 
and 40 mg) produced almost complete inhibition of 
bath SBP and DBP responses. Thus, the minimum 
effective dose of temocapril is <2.5 mg, and the top 
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of the dose-response curve apparently is reached at 
~20 mg with the Ang I dose used in this study. An 
attenuation of the SBP response to Ang I was still 
evident 23 h after intake of the 20- and 40-mg doses 
(inhibition of 15 ± 7 and 28 ± 9%, respectively). 
In the control group, administration of placebo 
had no effect on the pressor response to Ang I. 
Figure 2 shows the reproducibility of the responses 
to Ang I injection in the 4 placebo-treated volun-
teers in a 24-h period on the five separate occasions. 
Inhibition of plasma ACE activity in vitro 
The time course of ACE activity inhibition measured 
with the two different substrates is shown in Fig. 3, Major 
differences were noted in the discriminating power of the 
two methods of plasma ACE activity measurement. With 
the substrate Hip-Gly-Gly, ACE activity was reduced al-
most to zero by all doses of temocapril for ~4 h after drug 
administration, whereas duration of the effect on ACE 
activity was dose dependent. In contrast, inhibitory ef-
fects of temocapril on ACE activity measured with the 
substrate Z-Phe-His-Leu had a distinct dose-dependent 
relationship at peak effect, ranging from 68 ± 5% (2.5 mg) 
to 4 ± 0% (40 mg) inhibition in comparison to baseline 
values, At 24 h postdose, the degree of inhibition of 
plasma ACE activity was related to the dose of temoca-
pril with both substrates used, ranging from 68 ± 4% (2.5 
mg) to 93 ± 1% (40 mg) with Hip-Gly-Gly, and 14 ± 5% 
(2.5 mg) to 53 ± 6% (40 mg) with Z-Phe-His-Leu. 
Plasma Ang I and Ang II 
Plasma concentrations of Ang I and Ang II are shown 
in Table l, As shown in Fig. 4, plasma Ang I increased 
and plasma Ang II decreased rapidly and dose depen-
dently after intake of the ACE inhibitor. Plasma Ang II 
returned toward its baseline level after 23 h with all doses, 
but plasma Ang I invariably remained increased after ac-
tive drug. 
Inhibition of ACE aclivity in vivo 
The effects of different doses of temocapril and placebo 
on the time course of plasma Ang II/Ang I ratio are sum-
marized in Table 1 and Fig. 4. This index of in vivo ACE 
inhibition also showed clear dose dependency at peak 
effect. At this point, the degree of inhibition ranged from 
82 ± 4% (2.5 mg) to 99 ± 0% (40 mg), and at 23 h postdose 
the degree of inhibition was 44 ± 12 and 80 ± 3% for the 
2.5- and the 40-mg doses, respectively. 
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FIG. 3. Time course of plasma angiotensin-
converting enzyme (ACE) activity (mean + 
SEM) of 6 normal volunteers alter ingestion of 
2.5, 5, 10, 20, and 40 mg temocapril and of 4 
normal volunteers after ingestion of placebo on 
5 different days (n = 20). Left: Z-Phe-His-Leu 
substrate. Right: Hip-Gly-Gly substrate. Results 
are percentages of pretreatment ACE activity (Al 
Ao). 
J 
J 
~Il J 
lr J 
[J 
[J 
lr J 
[~ J 
[~ 
l 
[] 
[ ] 
ASSESSMENT OF ACE INHIBITION 483 
160 1 % or baseline Ang Il 1 o placebo 
140 /}! !~ $ 2.5 mg 120 ~ 5 mg • lümg 100 t~I o 20mg 80 J~/ 111 40mg 60 j % ofbaselme Ang Il /Ang 1 ratrnl 40 -6 ____ Ji 160 
20 ,;;; 140 ! 
7000 ° 
4 8 12 16 20 24 
120 /"! !-~ 
I 
1 % of baseline Ang 1 j 100 
\ \/ 1 
6000 
80 
5000 
4000 60 I~Î 3000 k\1 40 2000 20 ~â~i~~~· >'~~ 1000 .,,d't~t- -~1 
8 12 16 20 24 
0 4 8 12 16 20 24 Time(hours) 
FIG. 4. Time course of plasma angiotensin Il (Ang Il) (left, 
top) Ang 1 (left, bottom) and Ang 11/Ang 1 ratio (right) after 2.5, 
5, 10, 20, and 40 mg temocapril (n = 6) or placebo (n = 20) 
(mean + SEM). Results are percentages of respective pre-
treatment values. 
Temocapril and temocapril diacid 
plasma concentrations 
Plasma concentrations of temocapril and its diacid ac-
tive metabolite after the five doses of temocapril are 
shown in Fig. 5. After each dose of temocapril, plasma 
concentrations of the parent compound increased rapidly, 
peak values were measured at 1 h (first blood sample), 
and concentrations subsequently rapidly decreased to al-
most undetectable levels by -6 h. The rapid plasma clear-
ance of temocapril was associate with an increase in the 
concentration of temocapril diacid, formed by the dees-
terification of temocapril. Peak concentrations were ob-
served 1-2 h after drug administration. Concentrations of 
temocapril diacid were -10 times those of the parent 
drug. 
Correlations of effect with plasma temocapril 
diacid concentrations 
SBP and DBP pressor responses to Ang I showed close 
inverse correlation with the logarithm of the plasma di-
acid metabolite concentration (r = -0.81 and -0.88, p < 
0.001) (Fig. 6). Similarly, the effects on ACE activity 
measured in vivo, when expressed as the logarithm, also 
showed a good inverse correlation with the logarithm of 
the plasma diacid concentration (r = -0.85, p < 0,001) 
(Fig. 6). The correlations between the logarithm of the 
plasma diacid and the logarithm of ACE activity mea-
sured in vitro depended on the method of ACE measure-
ment: It was stronger with the substrate Z-Phe-His-Leu (r 
= -0.90, n = 148, p < 0.001) than with the substrate 
Hip-Gly-Gly (r = -0,81, n = 148, p < 0.001). 
Correlations of effects with ACE activity in vivo 
and in vitro 
The effects on SBP and DBP pressor responses to Ang 
1 showed good correlation with the logarithm of ACE-
activity in vivo (r = 0.76 and 0.81, respectively, n = 148, 
p < 0.001, (Fig. 7). With ACE-activity measured in vitro, 
the correlation depended also on the method used: r was 
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FIG. 5. Plasma temocapril (ng/ml) (left) and temocapril di-
acid (ng/ml) (right) concentration after ingestion of temoca-
pril 2.5, 5, 10, 20, and 40 mg (mean + SEM) by healthy vol-
unteers (n = 6). Concentrations of temocapril diacid were 
~10-fold those of the parent drug. 
0.83 and 0.67 (Fig. 7) with Z-Phe-His-Leu and Hip-Gly-
Gly, respectively. 
DISCUSSION 
ACE inhibiting compounds can be characterized 
with a high degree of accuracy by quantitating their 
effect on plasma ACE activity and on circulating 
levels of Ang I and Ang II (23). The Ang II/Ang I 
ratio is probably the best index by which to assess 
blockade of ACE activity (14). Recent development 
of a servo-photoplethysmograph capable of moni-
toring BP continuously and noninvasively at the fin-
ger permits clinical estimation of the effect of an 
ACE inhibitor on BP response to Ang I. This device 
has been demonstrated to correlate well with in-
traarterial pressure (24,25) and to be accurate for 
study of brief BP changes produced by vasoactive 
agents in humans (26). 
We wished to evaluate the accuracy of these dif-
ferent approaches to characterizing ACE inhibitors 
and particularly to compare inhibition of the pressor 
response to Ang I with plasma ACE activity and the 
circulating levels of the ACE inhibitor. For this pur-
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FIG. 6. Correlations between plasma temocapril diacid and 
angiotensin Il (Ang 11)/Ang 1 ratio (r = -0.85, n = 148) (left) 
and systolic blood pressure response to Ang 1 (r = -0.81, n 
= 148) (right). 
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FIG. 7. Correlation between systolic 
blood pressure (SBP) response to an-
giotensin 1(Ang1) (percentage of basal 
value) and Ang 11/Ang 1 ratio (left) (r = 
0.76, n = 148), and in vitro Ang-
converting enzyme (ACE) activity de-
termined with the Z-Phe-His-Leu sub-
strate (center) (r = 0.83, n = 148) and 
with the Hip-Gly-Gly substrate (right) (r 
= 0.67, n = 148). 
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pose, we used a new ACE inhibitor (CS-662, temo-
capril). Its potent diacid active metabolite was pre-
viously shown to have a relatively long duration of 
action (27 ,28). 
ACE activity measured in plasma provided dif-
ferent information depending on the method and 
substrate used. The Hip-Gly-Gly method showed 
long-lasting and intense inhibition of plasma ACE 
activity and did not detect any major differences 
between the five different doses (2.5-40 mg) at peak 
effect since almost complete inhibition was ob-
tained (Fig. 3). ln contrast, the Z-Phe-His-Leu 
method distinguished well between each dose at 
peak effect as well as during the 23 h after drug 
intake (Fig. 3). These data confirm results of plasma 
ACE activity measured in vitro provides no defini-
tive information if conventional assays are used. 
Depending on the substrate used and on the ACE 
inhibitor tested, these in vitro measurements may 
not accurately reflect in vivo ACE activity (13) and 
more sophisticated methods may be needed (29). 
In ACE inhibition, plasma Ang II concentration, 
measured after high-performance liquid chromatog-
raphy separation (21), appears to be the appropriate 
endpoint at which to evaluate the degree of renin-
angiotensin system blockade (13). Plasma Ang II 
levels are determined by ACE activity as well as by 
the precursor decapeptide' s concentration (Ang I), 
which increases significantly after ACE inhibition, 
which explains why plasma Ang II returned at 23 h 
toward its initial value even though the pressor ef-
fect of Ang I was still inhibited (Figs. 1 and 4). The 
plasma Ang II/ Ang I ratio takes into account the 
available decapeptide substrate and therefore ap-
pears to be the most appropriate index of in vivo 
ACE activity. 
The reproducibility of the SBP response to re-
peated administration of an Ang I test dose was 
evaluated in the 4 placebo-treated volunteers, for 
five 23-h periods, each period separated by a 
1-week interval. The coefficient of variation was 
18.4 ± 2.6% (mean ± SEM, range 13-24%, (Fig. 2), 
which corroborates our earlier observations (26). At 
peak, the 20- and 40-mg doses of temocapril in-
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duced almost complete inhibition of the SBP re-
sponse to Ang I (92 ± 2 and 98 ± 1%, respectively). 
In addition, with the highest dose, the pressor effect 
of Ang I of 28 ± 9% was still reduced 23 h after drug 
intake. 
With an ACE inhibitor, we showed for the first 
time that blockade of the pressor response to Ang I 
is closely related to the plasma level of the active 
compound, i.e., the diacid metabolite. In addition, 
the pressor response to Ang I also correlated 
strongly with ACE activity in vivo, the parameter 
we consider to reflect most accurately ACE inhibi-
tion (14,30). Consequently, if inhibition of plasma 
ACE activity is measured accurately, it predicts 
very well the reduction in Ang II-dependent BP that 
will be induced by an ACE inhibitor. The correla-
tion between plasma diacid levels and plasma ACE 
activity or the pressor response to Ang I was ana-
lyzed based on a log-linear relation. Indeed, these 
parameters are expected to exhibit a relation best 
described by a sigmoidal Emax curve. However, 
since we avoided high and low extremes of drug 
concentrations in this study, only the linear part of 
such a curve was explored and linear regression 
was calculated. 
Temocapril is a potent and well-tolerated new 
ACE inhibitor. With this drug, ACE activity mea-
sured in vivo by the plasma Ang II/Ang I ratio was 
shown to be an excellent predictor of the drug-
induced eff ect on Ang-dependent BP. 
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Characterization of the Angiotensin II Receptor 
Antagonist TCV-116 in Healthy Volunteers 
Etienne Delacrétaz, Jürg Nussberger, Jerôme Biollaz, Bernard Waeber, Hans R. Brunner 
Abstract The purpose of this study was to assess the inhib-
itory effect ofTCV-116, an orally active angiotensin II (Ang Ü) 
antagonist, on the pressor action of exogenous Ang II and to 
determine the compensatory rise in plasma renin activity and 
Ang II levels. Twenty-three male volunteers were treated for 8 
days in a double-blind fashion with either placebo or TCV-116 
(1, 2, or 4 mg PO daily) and challenged on the first, fourth, and 
eighth days with repeated bolus injections of Ang II. An 
additional 4 subjects received 8 mg PO daily in a single-blind 
fashion. The inhibitory effect on the systolic blood pressure 
response to Ang II was long lasting and clearly dose related. Six 
hours after 4 mg TCV-116, the systolic blood pressure response 
to a given dose of Ang II was reduced to 40±4% and 35±8% 
B lockade of the renin-angiotensin system has turned out to be a very effective treatment of hypertension and congestive heart failure. 1-4 
Today, angiotensin-converting enzyme (ACE) inhibitors 
are used as therapeutic agents, but originally the concept 
was established with angiotensin receptor antagonists. 
Saralasin ([Sar1 ,Ala8]angiotensin 11)5 was the first recep-
tor antagonist of angiotensin II (Ang II) administered to 
humans.6-8 Since this peptide is not orally active, long-
term antihypertensive treatment was not possible. Fur-
thermore, the antagonist exhibited significant inherent 
agonist activity.9 Therefore, most patients did not re-
spond with a decrease in blood pressure. Furukawa and 
coworkers10 have synthesized some imidazole derivatives 
that specifically block the Ang 11-induced vasoconstric-
tion. Important chemical modification of these initial 
molecules has led to the synthcsis of new orally active 
Ang II receptor antagonists. 11•12 Although most of the 
compounds specifically block the angiotensin type 1 
(AT1) receptor responsible for ail hitherto known Ang II 
actions, including vascular smooth muscle contrac-
tion, 13·14 some compounds that specifically bind to the 
AT2 receptors were also synthesized. 13•15-17 The first 
orally active AT1 receptor antagonist, DuP 753 (losar-
tan), was shown to effectively block the pressor effect of 
exogenous Ang 1118•19 and to reduce blood pressure of 
patients in a manner similar to ACE inhibitors.20•21 
Although losartan is a potent Ang II receptor antago-
nist, its therapeutic effect is probably mostly due to its 
active metabolite, EXP3174, which exhibits about 10-
fold higher affinity to the receptor.22 
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of baseline value on days 1 and 8, respectively. TCV-116 
induced a dose-related increase in plasma renin activity and 
Ang II levels that was more pronounced on the eighth than on 
the first day of drug administration. Despite this compensatory 
mechanism, the relation between the time-integrated systolic 
blood pressure response to Ang II and the time-integrated 
CV-11974 levels, the active metabolite of TCV-116, was not 
different between days 1 and 8. In conclusion, TCV-116 
appears to be a well-tolerated, orally active, potent, and 
long-lasting antagonist of Ang II in men. (Hypertension. 
1995;25:14-21.) 
Key Words " angiotensin II " aldosterone " renin • 
dose-response relationship, drug 
TCV-116, a new AT1 receptor antagonist, and its 
active metabolite (CV-11974) have been shown in dif-
ferent pharmacological studies to be approximately 10-
fold more potent than losartan and to have a long 
elimination half-life. The objectives of the present study 
were to assess the inhibitory effect of TCV-116 on the 
pressor action of exogenous Ang II in healthy volun-
teers, to determine the dose dependency and duration of 
the inhibitory effect, to evaluate the correlation of the 
inhibitory effect with serum levels of the active metabo-
lite CV-11974, and to determine the effect of the com-
pound on plasma Ang Il, aldosterone, and catechol-
amine levels. 
Methods 
Subjects 
Twenty-seven male volunteers aged 20 to 36 years (mean, 
26.0 years) and weighing between 48 and 85 kg (mean, 69.9 kg) 
were enrolled in the randomized, double-blind, placebo-con-
trolled parallel design dose-ranging study. Volunteers under-
went a complete physical evaluation, electrocardiogram, and 
routine blood and urine analyses before being included in the 
study. The study was conducted in accordance with the princi-
ples of the Declaration of Helsinki. The protocol was reviewed 
and approved by the institutional review committee before the 
study was started. The nature, purpose, and potential risks of 
the studywere explained to each volunteer, and written consent 
was obtained. 
Blood Pressure Measurement 
The pressor effect of exogenous challenges of Ang II was 
measured on the finger using a photoplethysmograph (Fi-
napres, Ohmeda). The measurement technique, which is a 
noninvasive method measuring digital artety blood pressure 
continuously through a cuff wrapped around the finger, was 
first described by Penaz in 1973.23 The monitor provides 
beat-to-beat blood pressure values ( systolic, diastolic, and 
mean) and heart rate. This device has been demonstrated to 
correlate well with intra-arterial pressure24•25 and to be accu-
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FIG 1. Structural formula of the angiotensin Il receptor antagonist 
TCV-116, or (±)-1-(cyclohexyloxycarbonyloxy)ethyl-2-ethoxy-1-
[[2' -(1 H-tetrazol-5-yl)biphenyl-4-yl]methyl]-1-H-benzimidazole-7-
carboxylate, and its active metabolite, CV-1197 4. 
rate for the study of short-lasting blood pressure changes by 
vasoactive agents in humans.26 Blood pressure and heart rate 
were continuously recorded on graduated paper 10 minutes 
before and at least 15 minutes after injection of each Ang II 
challenge. Peak blood pressure changes were calculated using 
these tracings. 
Study Design 
Throughout the study, volunteers were on a free sodium 
intake. No medication other than the study drug was allowed, 
neither were cigarette smoking and consumption of alcohol or 
caffeine-containing beverages and food. One week before the 
first study day, a dose-response curve to intravenous bolus 
injections of Ang II was established for each subject. The goal 
was to obtain a test dose able to increase systolic blood pressure 
(SBP) by 25 to 40 mm Hg. Ang II (Clinalfa) was dissolved in 
0.9% NaCI to achieve a concentration of 1 µ,g/mL. After a 
polytetrafluoroethylene cannula was placed in the antecubital 
vein and after a 30-minute resting period to reach a steady 
baseline blood pressure and heart rate, bolus injections were 
started at a dose of 10 ng/kg and increased thereafter every 15 
to 20 minutes by increments of 10 ng/kg until the required 
blood pressure increase was reached. This individual final test 
dose was then repeated at least twice and was subsequently 
used to assess the inhibitory effects of TCV-116 during the 
entire study. The median dose determined for Ang II chal-
lenges was 30 ng/kg (range, 10 to 60 ng/kg). The corresponding 
baseline responses (increase of SBP after Ang II challenges) 
were on average 31.1 mm Hg (range, 28.3 to 38.7 mm Hg). 
TCV-116 [( ± )-1-( cyclohexyloxycarbonyloxy)ethyl-2-ethoxy-
l-[[2' -(lH-tetrazol-5-yl)biphenyl-4-yl]methyl]- l-H-benzimid-
azole-7-carboxylate] (Fig 1) is the active metabolite of CV-
11974. In fact, CV-11974 was synthesized first, but its 
bioavailability was Jess than 5% in animais. Therefore, the 
prodrug, TCV-116, was developed by esterizing the carboxylic 
group of CV-11974 at position 7 of the benzimidazole ring (see 
Fig 1). After oral administration, 14C-labeled TCV-116 is not 
detected in plasma, whereas radiolabeled CV-11974 is pres-
ent.27 In vitro studies have shown that the inhibitory ef]'ect of 
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TCV-116 on the Ang II (10-8 mol/L)-induced contraction of 
rabbit aorta was approximately one thirtieth that of CV-
11974.27 Accordingly, it appears that the inhibitory activity 
resides almost exclusively in CV-11974. TCV-116 is absorbed 
and converted to the active metabolite CV-11974 (Fig 1). 
Results of in vitro studies with 14C-labeled CV-11974 showed 
that the protein binding of the compound was concentration 
independent over the range of 10 to 104 ng/mL. In rats, dogs, 
and humans, 99.6% to 99.8%, 96.7% to 97.5%, and 99.4% to 
99.6% of CV-11974 is bound to protein. 
TCV-116 was provided by Takeda Europe R&D Centre in 
the form of 1-, 2-, 4-, and 8-mg film-coated tablets. Placebo 
tablets were identical in appearance. The tablets were admin-
istered with 200 mL tap water. 
Volunteers received on the mornings of 8 consecutive days 
one dose of TCV-116 (1, 2, or 4 mg) or placebo. Thus, each 
dose or placebo was given in a double-blind fashion to 6 
volunteers, except the 1-mg dose, which was given to only 5 
volunteers because of a dropout at entry screening. The 8-mg 
dose was administered subsequently to 4 additional volunteers 
in a single-blind fashion, when it had become evident that doses 
up to 4 mg may not produce maximal inhibition of the Ang II 
pressor response. During study days 1 through 9, the volunteers 
came every day at 6:30 AM to the research facility having fasted 
overnight (from 10 PM). Supine blood pressure and heart rate 
were measured after a 45-minute supine resting period. On 
study days 1 through 8, the dose of TCV-116 or placebo was 
administered at 8 AM. On days 1 and 8, systolic and diastolic 
pressor effects of Ang II challenges were measured before and 
after drug or placebo intake. Venous cannulas were inserted 
into a vein in each forearm, one line for angiotensin injections 
and the other for blood sampling. The blood pressure-moni-
toring cuffwas wrapped around the third or fourth finger on the 
side used for blood sampling. After a period of bed rest of at 
least 45 minutes and approximately 45 minutes before TCV-
116 or placebo was given to the volunteers, the established test 
dose of Ang II (selected according to the predetermined 
dose-response curve) was administered. The effect of the drug 
was then monitored on days 1 and 8 using bolus injections of 
the Ang II test dose at 1, 2, 3, 4, 6, 8, 12, 24, and 36 hours after 
drug intake. Additional Ang II challenges were also performed 
on day 4 before and 2, 6, and 12 hours after TCV-116 or 
placebo administration. The volunteers remained fasting and in 
a supine position for 6 hours after drug administration; they 
then received a light meal and remained resting in bed or 
seatcd for 6 more hours (supine for 1 hour before each blood 
sampling). Between hours 12 and 22.5, they were allowed to 
\eave the hospital. At the end of the study, ail volunteers 
underwent routine and laboratory safety evaluation. 
Hormone and Drug Measurements 
On days 1 and 8, plasma renin activity (PRA), Ang II, 
aldosterone, norepinephrine, and epinephrine were measured 
immediately before and 2, 4, 6, 12, and 24 hours after drug or 
placebo intake. The same parameters were also measured on 
day 4 immediately before drug or placebo intake. Additional 
samples for the measurement of plasma concentrations of 
CV-11974, the active metabolite of TCV-116, were drawn on 
every day of the study immediately before drug intake and 
repeatedly on days 1 and 8 (days 1 and 8: 1, 2, 2.5, 3, 3.5, 4, 6, 
8, 12, and 24 hours; day 8: 30 and 36 hours after drug or 
placebo intake). Blood sampling was always performed imme-
diately before the next angiotensin challenge. Volunteers re-
mained in a supine position for 60 minutes before ail these 
blood samples. 
Blood samples (5 mL) for measurement of plasma CV-11974 
concentration were collected into heparinized tubes, and 
plasma was stored at - 70°C until analyzed. The active metab-
olite CV-11974 (molecular weight, 610.67) was analyzed by 
reversed-phase high-performance liquid chromatography 
(HPLC) after extraction from acidified serum into ethyl ether. 
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Systolic Blood Pressure Response to Angiotensin Il, Plasma CV-11974 and Angiotensin Il Concentrations, and 
Plasma Renin Activity Before and After Administration of TCV-116 or Placebo to Healthy Volunteers on Days 1 and 8 
SBP, % of Day 1 
Baseline CV-11974, ng/mL Ang Il, fmol/mL PRA, (ng/mL}/h 
Treatment 
Placebo (n=6) 
TCV-116, 1 mg (n=5} 
TCV-116, 2 mg (n=6) 
TCV-116, 4 mg (n=6} 
Time After 
Drug lntake, h Day 1 
0 100±0 
2 104±4 
4 97±7 
6 99±9 
24 101±5 
0 100±0 
2 93±8 
4 89±11 
6 82±9 
24 
0 
2 
4 
6 
94±9 
100±0 
85±9 
82±11 
67±9 
75±5 
Day 8 
100±11 
104±5 
100±4 
106±7 
Day 1 
0±0 
0.2±0.1 
0.3±0.1 
0±0 
0±0 
0±0 
4.2±0.5 
5.5±0.3 
4.4±0.5 
0±0 
0±0 
7.6±2.4 
12.7±1.6 
10.9±0.8 
0.9±0.3 
0±0 
23.5±2.7 
34.3±3.9 
Day8 
0±0 
0±0 
0±0 
0±0 
0±0 
0±0 
5.3±1.0 
8.8±1.2 
7.8±1.0 
0.4±0.3 
1.5±0.5 
12.4±2.1 
17.6±2.4 
14.2±1.7 
1.8±0.3 
3.3±0.9 
23.9±3.3 
42.8±9.1 
Day 1 
4.5±0.8 
5.5±0.7 
4.8±0.7 
6.3±1.0 
5.0±0.9 
3.2±0.6 
3.9±1.1 
5.6±1.0 
8.2±2.1 
5.5±1.1 
3.9±0.8 
7.6±2.1 
17.8±6.2 
20.8±6.4 
10.7±3.0 
Day8 
5.3±1.2 
6.4±1.5 
5.4±0.8 
7.2±1.5 
4.0±0.7 
5.9±1.0 
7.3±1.5 
10.2±3.4 
11.5±3.0 
6.7±1.6 
8.1±1.1 
16.3±3.0 
Day 1 
0.79±0.22 
0.83±0.22 
0.82±0.16 
1.05±0.29 
0.77±0.15 
0.65±0.1 
0.79±0.17 
1.17±0.25 
1.63±0.49 
1.26±0.23 
0.71 ±0.19 
1.39±0.33 
3.18±1.03 
3.93±1.13 
2.14±0.61 
0.90±0.26 
1.33±0.31 
3.99±1.21 
Day8 
0.91 ±0.20 
1.07±0.33 
0.83±0.26 
1.29±0.35 
0.81±0.18 
1.26±0.20 
1.50±0.28 
2.10±0.60 
2.14±0.56 
1.55±0.32 
1.52±0.17 
3.13±0.43 
3.17±0.40 
4.75±0.45 
2.62±0.43 
3.93±0.80 
5.98±1.28 
11.72±4.06 
24 
0 
2 
4 
6 
100±0 
87±8 
41±9 
40±4 
58±11 
99±7 
83±8 
71±7 
64±9 
51 ±12 
84±9 
82±11 
74±10 
58±8 
57±10 
70±9 
66±8 
51 ±13 
21±7 
35±8 27.7±3.5 42.8±12.5 
5.3±1.4 
7.9±1.9 
19.9±4.9 
21.3±4.7 
10.1 ±2.6 
14.5±1.5 
22.2±3.2 
12.1±2.5 
20.6±5.1 
31.9±7.0 
57.4±14.3 
57.0±7.7 
13.9±2.2 
14.2±5.5 
30.9±14.5 
39.4±20.7 
55.4±25.1 
11.6±0.7 
3.87±0.86 11.98±2.53 
TCV-116, 8 mg (n=4) 
24 
0 
2 
4 
6 
24 
100±0 
52±9 
22±3 
19±5 
49±6 
53±9 2.2±0.4 
44±16 0±0 
36±14 36.8±7.1 
16±6 47.4±6.4 
15±9 33.3±4.5 
53±13 3.8±0.5 
4.0±1.3 
3.9±1.8 
34.1±5.9 
48.2±7.0 
36.3±5.8 
4.9±0.8 
3.0±0.7 
10.1 ±2.8 
15.9±4.0 
22.1±6.5 
12.1±2.0 
1.99±0.53 
0.35±0.25 
1.74±0.52 
2.53±0.36 
4.18±1.20 
2.35±0.38 
3.28±0.57 
2.85±1.06 
5.85±2.46 
6.60±2.88 
7.25±3.04 
2.73±0.48 
SBP indicates systolic blood pressure; Ang, angiotensin; and PRA, plasma renin activity. For CV-1197 4, 1 ng/ml= 1.64 nmol/L; for PRA, 1 
(ng/ml)/h=0.77 (nmol/L}/h. 
Briefiy, 0.5 mL serum was acidified with 0.5 mL of 0.2 mol/L 
hydrochloric acid. After mixing, 5.0 mL ethyl ether was added 
to extract CV-11974 by shaking for 15 minutes. One hundred 
microliters of 10% propylene glycol in methanol was added to 
the organic extract before evaporation under nitrogen. The 
residue was taken up in 200 µ,Lof mobile phase A ( acetonitrile/ 
KH2P04 [20 mmol/L], pH adjusted to 3.5 with 85% H3P04). 
One hundred microliters was injected. A column-switching 
HPLC method was used. A fraction containing CV-11974 from 
column A was eluted by mobile phase A into column B. 
CV-11974 was separated from the coeluting endogenous com-
pounds using mobile phase B (acetonitrile/KH2P04 [20 mmol/ 
L], 34:66). A 10-port column-switching valve was used to 
contrai the time events. The detection limit of CV-11974 was 
0.8 ng/mL or 1.3 nmol/L in human serum. The extraction 
recovery of CV-11974 from serum was 70% and was consistent 
over the entire standard curve range. 
For the measurement of PRA, generated Ang I was trapped 
and quantitated by high-affinity antibodies. 28•29 Immunoreac-
tive Ang II was quantitatively extracted from plasma by revers-
ible adsorption to phenylsilyl silica and estimated by radioim-
munoassay using monoclonal antibodies against Ang II.30 
Plasma aldosterone was determined by a direct radioimmuno-
assay.31 Plasma norepinephrine and epinephrine levels were 
determined using the radioenzymatic method of Feuler and 
Johnson32 as modified for our laboratory.33 Subjects remained 
in a supine position for 30 minutes before blood sampling. 
The percent of baseline pressor response to Ang II was 
time-integrated up to 24 hours in calculating the area under the 
cmve according to a trapezoidal rule for each individual 
volunteer. The same was done for time integration of CV-
11974 concentration and PRA and Ang II plasma levels up to 
24 hours. 
Pharmacokinetic Calculations 
A one-compartment mode! after extravascular administra-
tion was fitted to the plasma data by extended least-squares 
nonlinear regression with the error mode! =v(l) (homoscedas-
tic mode!). In two subjects, a two-compartment mode! had to 
be used. The area under the time versus concentration time 
curve (AUC) was calculated using the trapezoidal rule in the 
ascending portion of the cmve and the log-trapezoidal rule for 
the descending concentrations and was extrapolated to infinity 
at day 1 and up to 24 hours at day 8 (one dosing interval). The 
(apparent) clearance (CL') was calculated assuming complete 
absorption and transformation of TCV-116 into CV-11974 as 
dose/AUC and the terminal half-life (tvi) as Ln(2)/,\z· The 
mean residence time (MRT) was calculated as (AUMC/ 
AUC)-MAT, where AUMC represents the area under the 
first moment of the concentration versus time cmve (to infinity) 
and MAT the mean formation time. 
Statistical Analysis 
Ali values are mean±SEM. Blood pressure and heart rate 
responses to the Ang II challenge were defined as the differ-
ence between the values before and after individual challenges 
and expressed as percent of the mean baseline response to the 
individual final test dose of Ang II. Statistical analysis was 
performed using ANOVA for repeated measures and paired t 
test with the Bonferroni adjustment for multiple comparisons 
(SUPERANOVA 1.1, Abacus Concepts, Inc). The time-integrated 
parameters (SBP response to Ang II, PRA, plasma drug, and 
Ang II concentrations) were analyzed by a two-factor ANOVA 
followed when required by a Fischer's protected least signifi-
cant difference test. The correlation coefficients were calcu-
lated when indicated by the least-squares method. A probabil-
ity value of less than .05 was considered significant. 
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FIG 2. A, Line graphs show effect of 8 
consecutive days of treatment (days 1 
[left] and 8 [right]) with four oral doses of 
TCV-116 (1, 2, 4, and 8 mg/d) or placebo 
on systolic blood pressure (SBP) re-
sponse to individually predetermined 
test dose of angiotensin Il (Ang Il) in 
healthy volunteers (mean±SEM). Base-
line response (100%) was determined 
before first drug or placebo administra-
tion. B, Bar graphs show time integral of 
inhibition of presser response to Ang Il 
challenges on days 1 (left) and 8 (right) of 
treatment with placebo or 1, 2, 4, and 8 
mg/d PO TCV-116. *P<.05, tP<.01. 
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Results 
Safety of Oral Administration of TCV-116 
No clinically significant adverse reaction was observed 
in any volunteer during the study. TCV-116 had no effect 
on (resting) supine or upright blood pressure and heart 
rate after the first administration or during the 8-day 
treatment. TCV-116 did not modify blood cell counts, 
routine laboratory tests, urine analyses, or electrocardio-
grams. Of the 24 volunteers collected for the initial 
randomization, 2 had to be withdrawn before adminis-
tration of the medication because of abnormal labora-
tory findings and only 1 of them could be replaced in 
time. 
Blood Pressure Response to Ang II 
The Table and Fig 2 show the dose-related inhibition 
of the SBP response to exogenous Ang II. Doses of 1, 2, 
4, and 8 mg induced a dose-related inhibition of the 
response to Ang II. On day 1, the peak inhibitory effect 
was reached between 4 and 8 hours after drug intake; 4 
hours after the 4-mg dose, the blood pressure response 
to Ang II decreased to 41±9% and 21±7% of the 
baseline response on days 1 and 8, respectively. The 
mean blood pressure response to Ang II of the 4 
volunteers treated with the 8-mg dose in a single-blind 
fashion decreased to 22±3% and 16±6% 4 hours after 
drug intake. On day 1, a significant attenuation of the 
blood pressure response to Ang II was still present 24 
hours after intake of the 2-, 4-, and 8-mg doses of 
TCV-116 (75±5%, P<.01; 58±11 %, P<.05; 49±6%, 
P<.01, respectively, versus predrug blood pressure re-
sponse). The integral of SBP response over 24 hours is 
represented in Fig 2B. The trough effect on day 8 
showed no statistically significant difference compared 
with the trough effect on day 1. Except for the 1-mg dose 
on day 1, any dose of TCV-116 significantly reduced the 
SBP response to Ang II, and this reduction was dose 
related. The time-integrated SBP response tended to 
decrease slightly more on day 8 than on day 1. 
Pharmacokinetics 
Plasma concentrations of TCV-116 were not detected. 
After the administration of TCV-116, its active metab-
olite CV-11974 appeared after a mean lag time of 1.0 
hour ( days 1 and 8) and reached a peak (Tmax) between 
3.5 and 6 hours. Its mean formation time was 1.2 and 1.3 
hours on days 1 and 8, respectively. The mean concen-
trations of CV-11974 are described in the Table and 
plotted in Fig 3(day1: Fig 3A, left; day 8: Fig 3A, right). 
Maximal concentrations (Tmax) and AUC values in-
creased in proportion to the dose after the three low 
doses but Jess than expected at the high dose. Except 
once in 2 subjects, the plasma concentrations declined 
monoexponentially with half-life periods of 3.5 hours 
(day 1) and 4.0 hours (day 8). Plasma levels were still 
measurable at 24 hours, and trough concentrations re-
mained unchanged from day 2 through day 8 for ail doses 
of TCV-116. MRT values were 8.1 and 9.7 hours on days 1 
and 8, respectively. The apparent clearance of CV-11974, 
its maximal possible clearance given the assumptions made 
in its calculation, were 0.25 L · h- 1 • kg- 1 on day 1 and 0.20 
L · h- 1 • kg- 1 on day 8. 
Dose-Effect Relations 
In Fig 4A, the mean inhibition of the pressure re-
sponse to exogenous Ang II challenge is plotted against 
the respective concentrations of CV-11974 for each dose 
and each time point (up to 24 hours) on day 1. The 
dose-effect relation shows a considerable dispersion of 
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FIG 3. A, Une graphs show time profile 
of mean plasma concentrations of CV-
1197 4, the active metabolite of TCV-
116, on days 1 (left) and 8 (right) treat-
ment with four oral doses of TCV-116 (1, 
2, 4, and 8 mg/d) (mean±SEM). B, Bar 
graphs show area under the concentra-
tion-time curve (AUC) of the active me-
tabolite CV-11974 on days 1 (left) and 8 
(right) of treatment with 1, 2, 4, and 8 
mg/d PO TCV-116. *P<.05, tP<.01, 
:j:P<.001. 
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left), which accounts for an anticlockwise hysteresis loop 
(Fig 4A, right) on day 1. This loop characterizes a slow 
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pressure while plasma concentrations of CV-11974 are 
increasing, and a sustained effect when drug concentra-
tions are falling. The time necessary to collapse both 
arms of the curve varies between 1 and 2 hours. This 
FIG 4. A, left, Scatterplot shows 
mean CV-11974 concentrations vs 
mean inhibition of systolic blood 
pressure (BP) response to angioten-
sin Il (Ang Il) after four oral doses of 
10 20 30 40 50 TCV-116 (1, 2, 4, and 8 mg/d) on day 
1. Right, Points are connected in a 
time-ascending fashion for each 
dose. B, Line graph shows time inte-
gral of the inhibition of the pressor 
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response to Ang Il challenge vs the 
area under the concentration-Ume 
curve (AUC) of the metabolite in 27 
volunteers on days 1 and 8 of an 
8-day treatment with placebo or 1, 2, 
4, and 8 mg/d PO TCV-116. Dashed 
and solid lines represent the linear 
correlation of days 1 and 8, respec-
tively. SBP indicates systolic blood 
pressure. 
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FIG 5. A, Line graphs show effect of 8 consecutive days 
of treatment with four oral doses of TCV-116 (1, 2, 4, and 
8 mg/d) or placebo on plasma renin activity (PRA) and 
immunoreactive angiotensin Il (Ang 11) on days 1 (left) and 
8 (right) (mean±SEM). B, Bar graphs show time integral of 
PRA and immunoreactive Ang Il on days 1 (left) and 8 
(right) of treatment with placebo or 1, 2, 4, and 8 mg/d PO 
TCV-116 in 27 volunteers. *P<.05, tP<.01. 
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loop in dose-effect relations exists for each individual 
volunteer (data not shown). On day 8, the loop is 
fiattened (data not shown). Furthermore, for a given 
plasma drug level, the degree of inhibition of the SBP 
response to Ang II seems to be higher on day 8 than on 
day 1. Fig 4B illustrates the same relation for the 
time-integrated data of individual subjects on days 1 and 
8 taking into account the duration of the drug effect (the 
integral of the percentage of inhibition over 24 hours 
was related to the AUC of CV-11974 during the same 
period). This time-integrated dose-effect relation 
showed a linear pattern without any plateau, although 
the maximal inhibition is reached with the higher CV-
11974 plasma concentrations. Although the magnitude 
of the inhibition of the blood pressure response to Ang 
II does not change, its duration is prolonged, leading to 
a linear increase of the time-integrated hemodynamic 
effect. 
Neurohumoral Variables 
The Table and Fig 5 depict PRA and Ang II plasma 
levels measured at the first and eighth administration of 
placebo or TCV-116. Both PRA and Ang II showed a 
marked dose-related increase 6 hours after drug intake, 
and this increase reached clearly higher values on day 8 
than on day 1. Both variables had already increased 
significantly 4 hours after administration of 2, 4, and 8 
mg TCV-116 on the first day (P<.05 versus placebo). 
Avery close correlation was found between PRA and 
plasma Ang II (r=.91, n=348, P<.001). There was also 
a negative correlation between the increase in PRA and 
the SEP response to exogenous Ang II (r= - .456, 
n=348, P<.001). Neither plasma norepinephrine nor 
plasma epinephrine (not shown) changed during the 
8-day administration of TCV-116. 
Fig 6 shows plasma aldosterone concentrations. 
Plasma aldosterone levels decreased after administra-
tion of single doses of TCV-116, but a similar decrease 
was also seen after placebo, refiecting the circadian 
variation in aldosterone concentrations. 
Discussion 
The present data demonstrate that TCV-116 is a 
potent, orally active Ang II antagonist with a relatively 
long duration of action. At peak effect (8 hours after 
drug intake), the 4-mg dose induced a 72±5% and 
77±4% reduction in the systolic and diastolic blood 
pressure responses to Ang II, respectively. With the 
three higher doses used, ie, 2, 4, and 8 mg, a definite 
blocking effect was still present 24 hours after drug 
intake (day 1). With these three higher doses, the trough 
inhibition of Ang II pressor effect was greater on day 8 
than on day 1, so that before drug intake on day 8, the 
pressor response to Ang II was only approximately 75% 
of the comparable response on day 1, suggesting that the 
drug exerts an effect that lasts for more than 24 hours. 
With repeated administration, no significant cumulative 
progressive enhancement of the blocking action could be 
observed at peak or trough. The dose dependency of the 
hemodynamic effect was clearly demonstrated with the 
four doses of TCV-116 throughout the treatment period 
(Fig 2). . 
The presence of constant trough levels from day 2 to day 
8 suggests that no accumulation is occurring. These resid-
ual levels account for a negligible fraction ( <6%) of the 
AUC values. The absence of a dose-proportional increase 
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Systolic Blood Pressure Response to Angiotensin Il, Plasma CV-11974 and Angiotensin Il Concentrations, and 
Plasma Renin Activity Before and After Administration of TCV-116 or Placebo to Healthy Volunteers on Days 1 and 8 
SBP, % of Day 1 
Baseline CV-11974, ng/mL Ang Il, fmol/mL PRA, (ng/mL)/h 
Time After 
Treatment Drug lntake, h Day 1 
Placebo (n=6) 0 100±0 
2 104±4 
4 97±7 
6 99±9 
24 101±5 
TCV-116, 1 mg (n=5) 0 100±0 
2 93±8 
4 89±11 
6 82±9 
24 94±9 
TCV-116, 2 mg (n=6) 0 100±0 
2 85±9 
4 82±11 
6 67±9 
24 75±5 
TCV-116, 4 mg (n=6) 0 100±0 
2 87±8 
4 41±9 
6 40±4 
24 58±11 
TCV-116, 8 mg (n=4) 0 100±0 
2 52±9 
4 22±3 
6 19±5 
24 49±6 
Day 8 
100±11 
104±5 
100±4 
106±7 
99±7 
83±8 
71±7 
64±9 
51 ±12 
84±9 
82±11 
74±10 
58±8 
57±10 
70±9 
66±8 
51±13 
21±7 
35±8 
53±9 
44±16 
36±14 
16±6 
15±9 
53±13 
Day 1 
0±0 
0.2±0.1 
0.3±0.1 
0±0 
0±0 
0±0 
4.2±0.5 
5.5±0.3 
4.4±0.5 
0±0 
0±0 
7.6±2.4 
12.7±1.6 
10.9±0.8 
0.9±0.3 
0±0 
23.5±2.7 
34.3±3.9 
27.7±3.5 
2.2±0.4 
0±0 
36.8±7.1 
47.4±6.4 
33.3±4.5 
3.8±0.5 
Day 8 
0±0 
0±0 
0±0 
0±0 
0±0 
0±0 
5.3±1.0 
8.8±1.2 
7.8±1.0 
0.4±0.3 
1.5±0.5 
12.4±2.1 
17.6±2.4 
14.2±1.7 
1.8±0.3 
3.3±0.9 
23.9±3.3 
42.8±9.1 
42.8±12.5 
4.0±1.3 
3.9±1.8 
34.1 ±5.9 
48.2±7.0 
36.3±5.8 
4.9±0.8 
Day 1 
4.5±0.8 
5.5±0.7 
4.8±0.7 
6.3±1.0 
5.0±0.9 
3.2±0.6 
3.9±1.1 
5.6±1.0 
8.2±2.1 
5.5±1.1 
3.9±0.8 
7.6±2.1 
17.8±6.2 
20.8±6.4 
10.7±3.0 
5.3±1.4 
7.9±1.9 
19.9±4.9 
21.3±4.7 
10.1 ±2.6 
3.0±0.7 
10.1±2.8 
15.9±4.0 
22.1 ±6.5 
12.1±2.0 
Day 8 
5.3±1.2 
6.4±1.5 
5.4±0.8 
7.2±1.5 
4.0±0.7 
5.9±1.0 
7.3±1.5 
10.2±3.4 
11.5±3.0 
6.7±1.6 
8.1 ±1.1 
16.3±3.0 
14.5±1.5 
22.2±3.2 
12.1±2.5 
20.6±5.1 
31.9±7.0 
57.4±14.3 
57.0±7.7 
13.9±2.2 
14.2±5.5 
30.9±14.5 
39.4±20.7 
55.4±25.1 
11.6±0.7 
Day 1 
0.79±0.22 
0.83±0.22 
0.82±0.16 
1.05±0.29 
0.77±0.15 
0.65±0.1 
0.79±0.17 
1.17±0.25 
1.63±0.49 
1.26±0.23 
0.71 ±0.19 
1.39±0.33 
3.18±1.03 
3.93±1.13 
2.14±0.61 
0.90±0.26 
1.33±0.31 
3.99±1.21 
3.87±0.86 
1.99±0.53 
0.35±0.25 
1.74±0.52 
2.53±0.36 
4.18±1.20 
2.35±0.38 
Day8 
0.91 ±0.20 
1.07±0.33 
0.83±0.26 
1.29±0.35 
0.81 ±0.18 
1.26±0.20 
1.50±0.28 
2.10±0.60 
2.14±0.56 
1.55±0.32 
1.52±0.17 
3.13±0.43 
3.17±0.40 
4.75±0.45 
2.62±0.43 
3.93±0.80 
5.98±1.28 
11.72±4.06 
11.98±2.53 
3.28±0.57 
2.85±1.06 
5.85±2.46 
6.60±2.88 
7.25±3.04 
2.73±0.48 
SBP indicates systolic blood pressure; Ang, angiotensin; and PRA, plasma renin activity. For CV-11974, 1 ng/mL=1.64 nmol/L; for PRA, 1 
(ng/ml)/h=0.77 (nmol/L)/h. 
Briefiy, 0.5 mL serum was acidified with 0.5 mL of 0.2 mol/L 
hydrochloric acid. After mixing, 5.0 mL ethyl ether was added 
to extract CV-11974 by shaking for 15 minutes. One hundred 
microliters of 10% propylene glycol in methanol was added to 
the organic extract before évaporation under nitrogen. The 
residue was taken up in 200 µLof mobile phase A ( acetonitrile/ 
KH2P04 [20 mmol/L], pH adjusted to 3.5 with 85% H3P04). 
One hundred microliters was injected. A column-switching 
HPLC method was used. A fraction containing CV-11974 from 
column A was eluted by mobile phase A into column B. 
CV-11974 was separated from the coeluting endogenous com-
pounds using mobile phase B (acetonitrile/KH2P04 [20 mmol/ 
L], 34:66). A 10-port column-switching valve was used to 
contrai the time events. The detection limit of CV-11974 was 
0.8 ng/mL or 1.3 nmol/L in human serum. The extraction 
recovery of CV-11974 from serum was 70% and was consistent 
over the entire standard curve range. 
For the measurement of PRA, generated Ang I was trapped 
and quantitated by high-affinity antibodies.28•29 Immunoreac-
tive Ang II was quantitatively extracted from plasma by revers-
ible adsorption to phenylsilyl silica and estimated by radioim-
munoassay using monoclonal antibodies against Ang II.30 
Plasma aldosterone was determined by a direct radioimmuno-
assay.31 Plasma norepinephrine and epinephrine levels were 
determined using the radioenzymatic method of Feuler and 
Johnson32 as modified for our laboratory.33 Subjects remained 
in a supine position for 30 minutes before blood sampling. 
The percent of baseline pressor response to Ang II was 
time-integrated up to 24 hours in calculating the area under the 
curve according to a trapezoidal rule for each individual 
volunteer. The same was done for time integration of CV-
11974 concentration and PRA and Ang II plasma levels up to 
24 l10urs. 
Pharmacokinetic Calculations 
A one-compartment mode! after extravascular administra-
tion was fitted to the plasma data by extended least-squares 
nonlinear regression with the error mode! =v(1) (homoscedas-
tic mode!). In two subjects, a two-compartment mode! had to 
be used. The area under the time versus concentration time 
curve (AUC) was calculated using the trapezoidal rule in the 
ascending portion of the curve and the log-trapezoidal rule for 
the descending concentrations and was extrapolated to infinity 
at day 1 and up to 24 hours at day 8 (one dosing interval). The 
(apparent) clearance (CL') was calculated assuming complete 
absorption and transformation of TCV-116 into CV-11974 as 
dose/AUC and the terminal half-life (t112) as Ln(2)/À,. The 
mean residence time (MRT) was calculated as (AUMC/ 
AUC)-MAT, where AUMC represents the area under the 
first moment of the concentration versus time curve (to infinity) 
and MAT the mean formation time. 
Statistical Analysis 
Ali values are mean±SEM. Blood pressure and heart rate 
responses to the Ang II challenge were defined as the differ-
ence between the values before and after individual challenges 
and expressed as percent of the mean baseline response to the 
individual final test dose of Ang II. Statistical analysis was 
performed using ANOV A for repeated measures and paired t 
test with the Bonferroni adjustment for multiple comparisons 
(SUPERANOVA 1.1, Abacus Concepts, Inc). The time-integrated 
parameters (SBP response to Ang II, PRA, plasma drug, and 
Ang Il concentrations) were analyzed by a two-factor ANOVA 
followed when required by a Fischer's protected least signifi-
cant difference test. The correlation coefficients were calcu-
lated when inclicated by the least-squares method. A probabil-
ity value of Jess than .05 was considered significant. 
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FIG 2. A, Line graphs show effect of 8 
consecutive days of treatment (days 1 
[left] and 8 [right]) with four oral doses of 
TCV-116 (1, 2, 4, and 8 mg/d) or placebo 
on systolic blood pressure (SBP) re-
sponse to individually predetermined 
test dose of angiotensin Il (Ang Il) in 
healthy volunteers (mean±:SEM). Base-
line response (100%) was determined 
before first drug or placebo administra-
tion. B, Bar graphs show time integral of 
inhibition of pressor response to Ang Il 
challenges on days 1 (left) and 8 (right} of 
treatment with placebo or 1, 2, 4, and 8 
mg/d PO TCV-116. *P<.05, tP<.01. 
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Results 
Safety of Oral Administration of TCV-116 
No clinically significant adverse reaction was obseived 
in any volunteer during the study. TCV-116 had no effect 
on (resting) supine or upright blood pressure and heart 
rate after the first administration or during the 8-day 
treatment. TCV-116 did not modify blood cell counts, 
routine laboratory tests, urine analyses, or electrocardio-
grams. Of the 24 volunteers collected for the initial 
randomization, 2 had to be withdrawn before adminis-
tration of the medication because of abnormal labora-
t01y findings and only 1 of them could be replaced in 
time. 
Blood Pressure Response to Ang II 
The Table and Fig 2 show the dose-related inhibition 
of the SBP response to exogenous Ang II. Doses of 1, 2, 
4, and 8 mg induced a dose-related inhibition of the 
response to Ang II. On day 1, the peak inhibitory effect 
was reached between 4 and 8 hours after drug intake; 4 
hours after the 4-mg dose, the blood pressure response 
to Ang II decreased to 41±9% and 21±7% of the 
baseline response on days 1 and 8, respectively. The 
mean blood pressure response to Ang II of the 4 
volunteers treated with the 8-mg dose in a single-blind 
fashion decreased to 22±3% and 16±6% 4 hours after 
drug intake. On day 1, a significant attenuation of the 
blood pressure response to Ang II was still present 24 
hours after intake of the 2-, 4-, and 8-mg doses of 
TCV-116 (75±5%, P<.01; 58±11 %, P<.05; 49±6%, 
P<.Ol, respectively, versus predrug blood pressure re-
sponse). The integral of SBP response over 24 hours is 
represented in Fig 2B. The trough effect on day 8 
showed no statistically significant difference compared 
with the trough effect on day 1. Except for the 1-mg dose 
on day 1, any dose of TCV-116 significantly reduced the 
SBP response to Ang II, and this reduction was dose 
related. The time-integrated SBP response tended to 
decrease slightly more on day 8 than on day 1. 
Pharmacokinetics 
Plasma concentrations of TCV-116 were not detected. 
After the administration of TCV-116, its active metab-
olite CV-11974 appeared after a mean lag time of 1.0 
hour (days 1 and 8) and reached a peak (Tmax) between 
3.5 and 6 hours. Its mean formation time was 1.2 and 1.3 
hours on days 1 and 8, respectively. The mean concen-
trations of CV-11974 are described in the Table and 
plotted in Fig 3(day1: Fig 3A, left; day 8: Fig 3A, right). 
Maximal concentrations (Tmax) and AUC values in-
creased in proportion to the dose after the three low 
doses but less than expected at the high dose. Except 
once in 2 subjects, the plasma concentrations declined 
monoexponentially with half-life periods of 3.5 hours 
( day 1) and 4.0 hours ( day 8). Plasma levels were still 
measurable at 24 hours, and trough concentrations re-
mained unchanged from day 2 through day 8 for ail doses 
of TCV-116. MRT values were 8.1 and 9.7 hours on days 1 
and 8, respectively. The apparent clearance of CV-11974, 
its maximal possible clearance given the assumptions made 
in its calculation, were 0.25 L · h-1 · kg-1 on day 1 and 0.20 
L · h-1 • kg-1 on day 8. 
Dose-Effect Relations 
In Fig 4A, the mean inhibition of the pressure re-
sponse to exogenous Ang II challenge is plotted against 
the respective concentrations of CV-11974 for each dose 
and each time point (up to 24 hours) on day 1. The 
dose-effect relation shows a considerable dispersion of 
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FIG 3. A, Line graphs show time profile 
of mean plasma concentrations of CV-
1197 4, the active metabolite of TCV-
116, on days 1 (left) and 8 (right) treat-
ment with four oral doses of TCV-116 (1, 
2, 4, and 8 mg/d) (mean±SEM). B, Bar 
graphs show area under the concentra-
tion-time curve (AUC) of the active me-
tabolite CV-11974 on days 1 (left) and 8 
(right) of treatment with 1, 2, 4, and 8 
mg/d PO TCV-116. *P<.05, tP<.01, 
:j:P<.001. 
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increasing, and a sustained effect when drug concentra-
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and solid lines represent the linear 
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FIG 5. A, Line graphs show effect of 8 consecutive days 
of treatment with four oral doses of TCV-116 (1, 2, 4, and 
8 mg/d) or placebo on plasma renin activity (PRA) and 
immunoreactive angiotensin Il (Ang Il) on days 1 (left) and 
8 (right) (mean±SEM). B, Bar graphs show time integral of 
PRA and immunoreactive Ang Il on days 1 (left) and 8 
(right) of treatment with placebo or 1, 2, 4, and 8 mg/d PO 
TCV-116 in 27 volunteers. *P<.05, tP<.01. 
• 0 0 
12 16 20 24 12 
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loop in dose-effect relations exists for each individual 
volunteer (data not shown). On day 8, the loop is 
fiattened (data not shown). Furthermore, for a given 
plasma drug level, the degree of inhibition of the SBP 
response to Ang II seems to be higher on day 8 than on 
day 1. Fig 4B illustrates the same relation for the 
time-integrated data of individual subjects on days 1 and 
8 taking into account the duration of the drug effect (the 
integral of the percentage of inhibition over 24 hours 
was related to the AUC of CV-11974 during the same 
period). This time-integrated dose-effect relation 
showed a linear pattern without any plateau, although 
the maximal inhibition is reached with the higher CV-
11974 plasma concentrations. Although the magnitude 
of the inhibition of the blood pressure response to Ang 
II does not change, its duration is prolonged, leading to 
a linear increase of the time-integrated hemodynamic 
effect. 
Neurohumoral Variables 
The Table and Fig 5 depict PRA and Ang II plasma 
levels measured at the first and eighth administration of 
placebo or TCV-116. Both PRA and Ang II showed a 
marked dose-related increase 6 hours after drug intake, 
and this increase reached clearly higher values on day 8 
than on day 1. Both variables had already increased 
significantly 4 hours after administration of 2, 4, and 8 
mg TCV-116 on the first day (P<.05 versus placebo). 
Avery close correlation was found between PRA and 
plasma Ang II (r=.91, n=348, P<.001). There was also 
a negative correlation between the increase in PRA and 
the SBP response to exogenous Ang II (r= - .456, 
n=348, P<.001). Neither plasma norepinephrine nor 
16 20 24 
plasma epinephrine (not shown) changed during the 
8-day administration of TCV-116. 
Fig 6 shows plasma aldosterone concentrations. 
Plasma aldosterone levels decreased after administra-
tion of single doses of TCV-116, but a similar decrease 
was also seen after placebo, refiecting the circadian 
variation in aldosterone concentrations. 
Discussion 
The present data demonstrate that TCV-116 is a 
potent, orally active Ang II antagonist with a relatively 
long duration of action. At peak effect (8 hours after 
drug intake), the 4-mg dose induced a 72±5% and 
77±4% reduction in the systolic and diastolic blood 
pressure responses to Ang II, respectively. With the 
three higher doses used, ie, 2, 4, and 8 mg, a definite 
blocking effect was still present 24 hours after drug 
intake (day 1). With these three higher doses, the trough 
inhibition of Ang II pressor effect was greater on day 8 
than on day 1, so that before drug intake on day 8, the 
pressor response to Ang II was only approximately 75% 
of the comparable response on day 1, suggesting that the 
drug exerts an effect that lasts for more than 24 hours. 
With repeated administration, no significant cumulative 
progressive enhancement of the blocking action could be 
observed at peak or trough. The dose dependency of the 
hemodynamic effect was clearly demonstrated with the 
four doses of TCV-116 throughout the treatment period 
(Fig 2). , 
The presence of constant trough levels from day 2 to day 
8 suggests that no accumulation is occurring. These resid-
ual levels account for a negligible fraction ( <6%) of the 
AUC values. The absence of a dose-proportional increase 
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in the AUC values between the 4- and 8-mg doses of 
TCV-116 could be due to nonlinear pharmacokinetics. 
Saturable absorption of TCV-116 or conversion to CV-
11974 at a high dose is another possibility, as suggested by 
the prolongation ofMRTvalues with increasing doses, that 
is also compatible with a lengthened absorption process. 
The CV-11974 concentration-blood pressure effect curve 
revealed an anticlockwise hysteresis loop, probably caused 
by pharmacokinetic influences determining the distribution 
of the drug to its site of action. 
PRA and Ang II levels exhibited dose-related com-
pensatory increases as described with previously 
tested Ang II antagonists.6 •34 The rise in renin and 
Ang I is similar to that observed after administration 
of ACE inhibitors.35 With repeat administration of 
TCV-116, the increase was accentuated, the PRA and 
Ang II levels being much higher on day 8 than on day 
1. The greater increase on day 8 than on day 1 in the 
PRA and Ang II values probably reflects the indirect 
effects of prolonged Ang II inhibition on sodium 
balance. The long duration of the blocking effect of 
TCV-116 is also reflected in the PRA and Ang II 
levels. Thus, 24 hours after the administration of 2, 4, 
or 8 mg, PRA and Ang II remained increased. 
As expected, Ang II plasma levels were strongly 
correlated with PRA, and the response of bath variables 
was inversely correlated with the SBP response to Ang II 
challenges. However, when individual data are consid-
ered, a substantial variability in these reactive increases 
becomes evident, as observed previously with losartan.22 
Therefore, the SBP response to Ang II challenges rather 
than the response of circulating levels of renin or Ang II 
should be used to predict the degree of Ang II receptor 
blockade in the individual subject. 
Can such high Ang II plasma levels after an 8-day 
treatment with an Ang II antagonist finally reduce the 
effect of the Ang II antagonist? This is a priori unlikely 
to occur, because the exogenous Ang II probably in-
duces much higher Ang II plasma levels than those 
occurring during the compensatory increase in renin 
secretion. Furthermore, the fact that for a given plasma 
CV-11974 level the degree of inhibition of the pressor 
response to Ang II tends to be greater on day 8 than on 
day 1 (Figs 2 and 4B) also suggests that the levcl of 
DAY 8 
FIG 6. Line graphs show effect of 8 
consecutive days of treatment with 
four oral doses of TCV-116 (1, 2, 4, 
and 8 mg/d} or placebo on plasma 
aldosterone levels on days 1 (left) and 
8 (right). 
8 12 16 20 24 
circulating Ang II has no measurable influence on the 
blocking effect of the AT1 antagonist. 
No effect of the Ang II antagonist on plasma aldoste-
rone could be demonstrated. Indeed, plasma aldoste-
rone levels decreased in treated subjects in a manner 
similar to that in the contrai group on placebo. This 
decrease in aldosterone levels is mainly due to the 
circadian rhythm of aldosterone secretion.36 
The most relevant question clinically is how TCV-
116 will compare as a therapeutic agent with the 
varions agents currently available for blockade of the 
renin-angiotensin system. Obviously, results from the 
present study cannot provide any conclusive answer to 
this question because the drug was administered only 
to healthy volunteers. Nevertheless, it is already evi-
dent that this Ang II antagonist exhibits features that 
make it appear promising as a therapeutic agent. As 
with losartan, 18·19 it is orally active and does not seem 
to have any agonist effect. With the use of ACE 
inhibitors, the antihypertensive effect has been shown 
to be well correlated with the decrease in plasma Ang 
II concentration. Furthermore, blockade of the pres-
sor effect of exogenous angiotensin has been shown to 
be strongly correlated with plasma Ang II37 concen-
tration. Consequently, since doses of 4 to 8 mg induce 
a more than 75% blockade of the pressor effect 
of Ang II in our study, we speculate that the oral 
antihypertensive dose of TCV-116 will be in the range 
of 4 mg/d. A similar projection was made with losar-
tan. This agent was shown to maximally inhibit the 
pressor response to Ang II with doses less than 
40 mg but less than or equal to 80 mg18; the full 
antihypertensive effect was subsequently obtained 
with 50 mg/d.21,38-40 
In conclusion, TCV-116 appears to be a well-toler-
ated, orally active, patent, and long-lasting antagonist of 
Ang II in men. TCV-116 induced neurohumoral com-
pensatmy mechanisms that did not decrease its effect as 
measured by inhibition of blood pressure response to 
exogenous Ang II. 
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